Latest Cancer TreatmentsDr. Mohammadreza Dabiri
Dr. Mohammadreza Dabiriفارسی
Clinical tool

Lung Cancer TNM Staging Calculator (9th Edition)

From T, N and M to stage 0–IVB by the IASLC 9th edition, with the changes from the 8th edition

Updated: 28 October 20261 min read2 references

Non-small cell lung cancer staging by the 9th edition of TNM (IASLC, from 2025); one table serves both clinical and pathological stage.

This calculator needs JavaScript; the formula and its interpretation are in the text of this page.

An aid for clinicians; it does not replace clinical judgement, local protocols or the drug label. Double-check every result before prescribing.

Changes in the 9th edition

  • N2 now has two subgroups: N2a, involvement of a single ipsilateral mediastinal or subcarinal station, and N2b, involvement of multiple mediastinal stations [1].
  • M1c now has two subgroups: M1c1, multiple extrathoracic metastases in one organ system, and M1c2, in multiple organ systems; both remain stage IVB [1].
  • These combinations changed stage: T1N1 from IIB to IIA, T1N2a from IIIA to IIB, T3N2a from IIIB to IIIA, and T2aN2b and T2bN2b from IIIA to IIIB [1]. All other combinations keep their 8th-edition stage [1, 2].

Practical notes

  • The 9th-edition proposals were tested on more than 76,000 patients with non-small cell lung cancer in the IASLC international database, using both clinical and pathological stage [1].
  • The prefix c is used for clinical stage (before treatment) and p for pathological stage (after surgery).
  • For a plain explanation of the stages and treatment for patients, see lung cancer.

Related cancer types

Lung cancer

Treatment regimens (physicians)

Trastuzumab deruxtecan (T-DXd, Enhertu): dose and monitoringCarboplatin, pemetrexed and pembrolizumab (KEYNOTE-189)Carboplatin, paclitaxel and pembrolizumab (KEYNOTE-407)Carboplatin-etoposide with atezolizumab or durvalumab in small cell lung cancerDurvalumab after chemoradiotherapy in stage 3 lung cancer (PACIFIC)Pembrolizumab alone in lung cancer with high PD-L1 (KEYNOTE-024)Osimertinib with pemetrexed and platinum (FLAURA2)Amivantamab with lazertinib (MARIPOSA)Adjuvant alectinib after surgery for ALK-positive lung cancer (ALINA)

Physician tools and lessons

Khorana Score (Cancer-Associated Thrombosis Risk)Should I Be Screened for Lung Cancer? (Pack-Year Calculator)10 cheap steps that save patients' livesDrug interactions with oral anticancer drugs: CYP3A4, acid suppressants and anticoagulantsManagement of brain metastasesMalignant pleural effusion: drainage, pleurodesis or an indwelling catheter

References

2 references
Show all referencesClose the reference list

Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.

  1. 1
    The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung CancerRami-Porta R, Nishimura KK, Giroux DJ, et al · J Thorac Oncol · 2024;19:1007-1027
    DOIPubMed Back to text: 1 2 3 4 5
  2. 2
    The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung CancerGoldstraw P, Chansky K, Crowley J, et al · J Thorac Oncol · 2016;11:39-51
    DOIPubMed Back to text

This page is based on reputable scientific sources and was last updated on 28 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.

Printed from the website; the full and up-to-date version: https://drdabiri.com/en/tools/lung-cancer-staging-tnm/

Related pages

27 October 2026 Should I Be Screened for Lung Cancer? (Pack-Year Calculator) Pack-year calculator and lung cancer screening eligibility for low-dose CT according to the US Preventive Services Task Force (2021). 27 October 2026 Localised Prostate Cancer Risk Group Calculator Tool to assign the risk group of localised prostate cancer from PSA, ISUP grade group and clinical stage, with the suggested treatment for each group. 27 October 2026 Child-Pugh and ALBI Score Calculator in Liver Cancer Child-Pugh score and ALBI grade calculator to assess liver function in hepatocellular carcinoma (HCC) and choose treatment according to BCLC.